Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature.
Meta-analysis
Prognosis factors
Survival
Systemic sclerosis
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
03 04 2019
03 04 2019
Historique:
received:
19
11
2018
accepted:
18
03
2019
entrez:
5
4
2019
pubmed:
5
4
2019
medline:
9
4
2020
Statut:
epublish
Résumé
Data on survival and prognosis factors in incident cohorts are scarce in systemic sclerosis (SStc). To describe survival, standardized mortality ratio (SMR), and prognosis factors in systemic sclerosis (SSc), we analyzed a multicenter French cohort of incident patients and performed a systematic review of the literature and meta-analysis. A multicenter, French cohort study was conducted between January 1, 2000, and December 31, 2013. Patients were followed-up until July 1, 2016. A systematic review of the literature was carried out in MEDLINE and EMBASE up to July 2017. Meta-analysis was performed using all available data on SMR and hazard ratios of prognosis factors. A total of 625 patients (493 females, 446 lcSSc) were included. During the study period, 104 deaths (16.6%) were recorded and 133 patients were lost to follow-up. Overall survival rates at 1, 3, 5, and 10 years from diagnosis were 98.0%, 92.5%, 85.9%, and 71.7% respectively in the French cohort. Overall SMR was 5.73 (95% CI 4.68-6.94). Age at diagnosis > 60 years, diffuse cutaneous SSc, scleroderma renal crisis, dyspnea, 6-min walking distance (6MWD), forced vital capacity < 70%, diffusing capacity of the lungs for carbon monoxide < 70%, pulmonary hypertension (PH), telangiectasia, valvular disease, malignancy, anemia, and CRP > 8 mg/l were associated with a poorer survival after adjustment. Eighteen studies (11,719 patients) were included in the SMR meta-analysis and 36 studies (26,187 patients) in the prognosis factor analysis. Pooled SMR was 3.45 (95%CI 3.03-3.94). Age at disease onset, male sex, African origin, diffuse cutaneous SSc, anti-Scl70 antibodies, cardiac and renal involvement, interstitial lung disease, PH, and malignancy were significantly associated with a worse prognosis. Anti-centromere antibodies were associated with a better survival. Overall, our study highlights a high mortality rate in SSc patients and confirms previously described prognosis factors related to skin extension and organ involvement while identifying additional prognosis factors such as autoantibody status, telangiectasia, 6MWD, and valvular disease.
Sections du résumé
BACKGROUND
Data on survival and prognosis factors in incident cohorts are scarce in systemic sclerosis (SStc). To describe survival, standardized mortality ratio (SMR), and prognosis factors in systemic sclerosis (SSc), we analyzed a multicenter French cohort of incident patients and performed a systematic review of the literature and meta-analysis.
METHODS
A multicenter, French cohort study was conducted between January 1, 2000, and December 31, 2013. Patients were followed-up until July 1, 2016. A systematic review of the literature was carried out in MEDLINE and EMBASE up to July 2017. Meta-analysis was performed using all available data on SMR and hazard ratios of prognosis factors.
RESULTS
A total of 625 patients (493 females, 446 lcSSc) were included. During the study period, 104 deaths (16.6%) were recorded and 133 patients were lost to follow-up. Overall survival rates at 1, 3, 5, and 10 years from diagnosis were 98.0%, 92.5%, 85.9%, and 71.7% respectively in the French cohort. Overall SMR was 5.73 (95% CI 4.68-6.94). Age at diagnosis > 60 years, diffuse cutaneous SSc, scleroderma renal crisis, dyspnea, 6-min walking distance (6MWD), forced vital capacity < 70%, diffusing capacity of the lungs for carbon monoxide < 70%, pulmonary hypertension (PH), telangiectasia, valvular disease, malignancy, anemia, and CRP > 8 mg/l were associated with a poorer survival after adjustment. Eighteen studies (11,719 patients) were included in the SMR meta-analysis and 36 studies (26,187 patients) in the prognosis factor analysis. Pooled SMR was 3.45 (95%CI 3.03-3.94). Age at disease onset, male sex, African origin, diffuse cutaneous SSc, anti-Scl70 antibodies, cardiac and renal involvement, interstitial lung disease, PH, and malignancy were significantly associated with a worse prognosis. Anti-centromere antibodies were associated with a better survival.
CONCLUSIONS
Overall, our study highlights a high mortality rate in SSc patients and confirms previously described prognosis factors related to skin extension and organ involvement while identifying additional prognosis factors such as autoantibody status, telangiectasia, 6MWD, and valvular disease.
Identifiants
pubmed: 30944015
doi: 10.1186/s13075-019-1867-1
pii: 10.1186/s13075-019-1867-1
pmc: PMC6446383
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
86Références
Arthritis Rheumatol. 2017 May;69(5):1067-1077
pubmed: 28029745
Semin Arthritis Rheum. 2014 Oct;44(2):208-19
pubmed: 24931517
Rheumatology (Oxford). 2003 Apr;42(4):534-40
pubmed: 12649400
Arthritis Rheum. 2013 Sep;65(9):2412-23
pubmed: 23740572
Autoimmun Rev. 2014 Oct;13(10):1026-34
pubmed: 25182204
Arthritis Rheum. 2013 Nov;65(11):2737-47
pubmed: 24122180
Arthritis Rheum. 2010 Sep;62(9):2787-95
pubmed: 20506513
Ann Rheum Dis. 2008 Jan;67(1):59-63
pubmed: 17519276
Rheumatol Int. 2017 Jan;37(1):75-84
pubmed: 26497313
Tissue Antigens. 2007 Apr;69(4):305-12
pubmed: 17389013
Clin Exp Rheumatol. 2012 Mar-Apr;30(2 Suppl 71):S30-7
pubmed: 22338601
Medicine (Baltimore). 2013 Jul;92(4):191-205
pubmed: 23793108
Clin Exp Rheumatol. 2010 Mar-Apr;28(2 Suppl 58):S18-27
pubmed: 20804663
Scand J Rheumatol. 2011;40(5):373-8
pubmed: 21388247
Rheumatology (Oxford). 2009 Mar;48(3):304-8
pubmed: 19174571
Scand J Rheumatol. 2017 May;46(3):226-235
pubmed: 27601074
Ann Rheum Dis. 2010 Oct;69(10):1809-15
pubmed: 20551155
J Am Soc Echocardiogr. 2016 Apr;29(4):277-314
pubmed: 27037982
Arthritis Rheum. 2003 Aug;48(8):2246-55
pubmed: 12905479
Arthritis Rheum. 2009 Oct 15;61(10):1403-11
pubmed: 19790132
Arthritis Res Ther. 2017 Dec 15;19(1):279
pubmed: 29246248
Arthritis Rheum. 2013 Jul;65(7):1913-21
pubmed: 23576072
Rheumatology (Oxford). 2012 Jun;51(6):1027-36
pubmed: 22223705
QJM. 2010 Feb;103(2):109-15
pubmed: 19966313
Rheumatol Int. 2017 Jul;37(7):1101-1109
pubmed: 28555363
Ann Rheum Dis. 1998 Nov;57(11):682-6
pubmed: 9924211
Medicine (Baltimore). 2002 Mar;81(2):139-53
pubmed: 11889413
Arthritis Rheumatol. 2014 Jun;66(6):1625-35
pubmed: 24591477
Arthritis Rheum. 2012 Sep;64(9):2986-94
pubmed: 22576620
Rheumatology (Oxford). 2010 Jun;49(6):1112-7
pubmed: 20223816
J Rheumatol. 2014 Nov;41(11):2193-200
pubmed: 25274896
JAMA Dermatol. 2018 Jul 1;154(7):796-805
pubmed: 29799952
Arthritis Rheum. 2011 May;63(5):1182-9
pubmed: 21391198
Medicine (Baltimore). 2015 Oct;94(43):e1728
pubmed: 26512564
Semin Arthritis Rheum. 2010 Feb;39(4):285-93
pubmed: 19782387
Rheumatol Int. 2016 Jul;36(7):925-34
pubmed: 27061806
Semin Arthritis Rheum. 2010 Feb;39(4):269-77
pubmed: 18706680
Ann Rheum Dis. 2014 Jun;73(6):1060-6
pubmed: 23606705
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Ann Rheum Dis. 2008 Jan;67(1):31-6
pubmed: 17267515
Rheumatology (Oxford). 2003 Jan;42(1):71-5
pubmed: 12509616
Rheumatology (Oxford). 2016 Feb;55(2):315-9
pubmed: 26359329
Br J Rheumatol. 1996 Nov;35(11):1122-6
pubmed: 8948299
J Rheumatol. 2012 Oct;39(10):1971-8
pubmed: 22896025
Clin Rheumatol. 2010 Mar;29(3):297-302
pubmed: 19957002
Ann Rheum Dis. 2017 Nov;76(11):1897-1905
pubmed: 28835464
Br J Rheumatol. 1998 Jul;37(7):750-5
pubmed: 9714351
Semin Arthritis Rheum. 2005 Apr;34(5):714-20
pubmed: 15846586
J Rheumatol. 1995 Nov;22(11):2100-2
pubmed: 8596151
Medicine (Baltimore). 2002 Mar;81(2):154-67
pubmed: 11889414
J Clin Epidemiol. 2001 Apr;54(4):343-9
pubmed: 11297884
Clin Rheumatol. 2014 Feb;33(2):197-205
pubmed: 23942767
Arthritis Rheum. 1980 May;23(5):581-90
pubmed: 7378088
Medicine (Baltimore). 2014 Mar;93(2):73-81
pubmed: 24646463
Arthritis Rheum. 1999 Dec;42(12):2660-5
pubmed: 10616015
Ann Rheum Dis. 2011 Oct;70(10):1788-92
pubmed: 21784727
Clin Rheumatol. 2013 Oct;32(10):1533-9
pubmed: 23812618
Q J Med. 1992 Feb;82(298):139-48
pubmed: 1620814
Ann Rheum Dis. 2007 Jul;66(7):940-4
pubmed: 17329309
Rheumatology (Oxford). 2012 Jun;51(6):1017-26
pubmed: 21900368
J Med Assoc Thai. 2002 Nov;85(11):1204-9
pubmed: 12546318
Am J Med. 2005 Jan;118(1):2-10
pubmed: 15639201
Autoimmun Rev. 2017 May;16(5):461-468
pubmed: 28285170
J Rheumatol. 2013 Jul;40(7):1127-33
pubmed: 23637316
J Clin Epidemiol. 1988;41(2):193-205
pubmed: 3257255